Lv41
760 积分 2024-06-11 加入
Nanobody-Engineered Bispecific IL-18 Mimetics Drive Antitumor Immunity by Engaging CD8+ T Cells and Evading IL-18BP in Preclinical Models
8小时前
求助中
Natural Killer Cell Signaling Pathways
2个月前
已完结
Stress Factors in mAb Drug Substance Production Processes: Critical Assessment of Impact on Product Quality and Control Strategy
2个月前
已完结
A tetraspecific engager armed with a non-alpha IL-2 variant harnesses natural killer cells against B cell non-Hodgkin lymphoma
3个月前
已完结
A brief introduction of IgG-like bispecific antibody purification: Methods for removing product-related impurities
3个月前
已完结
Non-viral delivery of RNA for therapeutic T cell engineering
5个月前
已完结
CAR T cells vs bispecific antibody as third- or later-line large B-cell lymphoma therapy: a meta-analysis
9个月前
已完结
Comparison of CAR T-cell vs. bispecific antibody as third- or later-line large B-cell lymphoma therapy: A Meta-analysis
9个月前
已关闭
Engineering Macrophages for Cancer Immunotherapy and Drug Delivery
9个月前
已完结
CD16A-Specific Tetravalent Bispecific Immune Cell Engagers Potently Induce Antibody-Dependent Cellular Phagocytosis (ADCP) on Macrophages
9个月前
已关闭
皖公网安备34019202002308
